Retour

Verrica Pharmaceuticals to Present at Upcoming Investor Conferences

Calendar Calendar of Events

WEST CHESTER, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica Pharmaceuticals’ President and Chief Executive Officer, will present at the following investor conferences:

GlobeNewswire Inc. • 09/05/2024 à 13:30:00
Verrica Pharmaceuticals Inc. Common Stock
Address: 10 NORTH HIGH STREET
Postal Code: 19380
City: WEST CHESTER
State: PA
Phone Number: 484-453-3300
Website: https://www.verrica.com
Status: Active
Company Info

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

List Date2018-06-15
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001660334
Composite figiBBG00L03BYB7
Share Class figiBBG00L03BZ24
Market Cap367,781,860 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees100
Share Class Shares Outstanding42420000
Weighted Shares Outstanding42420053
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
8.68
9.17
9.095
9.14
9.335
Variance
-5.55%
0.82%
-4.16%
-2.09%
22.67%
Open
9.19
9.095
9.49
9.335
7.61
Highest
9.324
9.645
9.95
11.363
9.579
Lowest
9.296
9.615
9.95
11.312
9.561
History
PeriodVarhighestlowest
1 week
14.06%
9.579
9.296
1 month
18.22%
7.342
6.861
3 month
26.99%
6.835
4.799
6 month
148%
3.74
3.37
1 year
43.95%
6.03
2.86
3 year
-22.98%
12.02
1.77
5 year
-0.34%
9.16
1.77
10 year
-56.6%
22
1.77
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-08 2023-11-09 UNPUB
Assets 68,639,000 62,201,000 97,148,000 UNPUB
Current Assets 63,097,000 56,777,000 91,725,000 UNPUB
Current Liabilities 2,643,000 5,731,000 11,374,000 UNPUB
Equity 64,846,000 55,400,000 42,303,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 64,846,000 55,400,000 42,303,000 UNPUB
Liabilities 3,793,000 6,801,000 54,845,000 UNPUB
Liabilities And Equity 68,639,000 62,201,000 97,148,000 UNPUB
Noncurrent Assets 5,542,000 5,424,000 5,423,000 UNPUB
Noncurrent Liabilities 1,150,000 1,070,000 43,471,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-08 2023-11-09 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 25,679,000 -4,812,000 29,168,000 UNPUB
Net Cash Flow, Continuing 25,679,000 -4,812,000 29,168,000 UNPUB
Net Cash Flow From Financing Activities 30,280,000 -84,000 44,044,000 UNPUB
Net Cash Flow From Financing Activities, Continuing 30,280,000 -84,000 44,044,000 UNPUB
Net Cash Flow From Investing Activities -11,000 -59,000 -65,000 UNPUB
Net Cash Flow From Investing Activities, Continuing -11,000 -59,000 -65,000 UNPUB
Net Cash Flow From Operating Activities -4,590,000 -4,669,000 -14,811,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -4,590,000 -4,669,000 -14,811,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-08 2023-11-09 UNPUB
Comprehensive Income/Loss -6,589,000 -10,990,000 -24,802,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -6,589,000 -10,990,000 -24,802,000 UNPUB
Other Comprehensive Income/Loss 0 -10,990,000 -24,802,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-08 2023-11-09 UNPUB
Basic Earnings Per Share 0 0 -1 UNPUB
Benefits Costs and Expenses 6,626,000 0 0 UNPUB
Cost Of Revenue UNPUB UNPUB 300,000 UNPUB
Costs And Expenses 6,626,000 11,798,000 26,834,000 UNPUB
Diluted Earnings Per Share 0 0 -1 UNPUB
Gross Profit UNPUB UNPUB 2,617,000 UNPUB
Income/Loss From Continuing Operations After Tax -6,589,000 -10,990,000 -24,802,000 UNPUB
Income/Loss From Continuing Operations Before Tax -6,589,000 182,000 2,917,000 UNPUB
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating 0 0 1,657,000 UNPUB
Net Income/Loss -6,589,000 -10,990,000 -24,802,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -6,589,000 -10,990,000 -24,802,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -6,589,000 -10,990,000 -24,802,000 UNPUB
Operating Expenses 7,126,000 11,798,000 26,834,000 UNPUB
Operating Income/Loss -7,089,000 -11,616,000 -23,917,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 37,000 182,000 2,917,000 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-09 2022-08-11 2022-11-07 2023-03-06
Assets 71,617,000 63,436,000 49,147,000 44,721,000
Current Assets 65,772,000 57,341,000 43,395,000 39,115,000
Current Liabilities 44,800,000 45,711,000 3,078,000 3,459,000
Equity 25,418,000 16,333,000 44,765,000 40,033,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 25,418,000 16,333,000 44,765,000 40,033,000
Liabilities 46,199,000 47,103,000 4,382,000 4,688,000
Liabilities And Equity 71,617,000 63,436,000 49,147,000 44,721,000
Noncurrent Assets 5,845,000 6,095,000 5,752,000 5,606,000
Noncurrent Liabilities 0 0 1,304,000 1,229,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-09 2022-08-11 2022-11-07 2023-03-06
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 34,655,000 -4,977,000 -12,957,000 18,521,000
Net Cash Flow, Continuing 34,655,000 -4,977,000 -12,957,000 18,521,000
Net Cash Flow From Financing Activities -18,000 -1,000 -16,851,000 -16,870,000
Net Cash Flow From Financing Activities, Continuing -18,000 -1,000 -16,851,000 -16,870,000
Net Cash Flow From Investing Activities 43,013,000 2,205,000 2,069,000 54,041,000
Net Cash Flow From Investing Activities, Continuing 43,013,000 2,205,000 2,069,000 54,041,000
Net Cash Flow From Operating Activities -8,340,000 -7,181,000 1,825,000 -18,650,000
Net Cash Flow From Operating Activities, Continuing -8,340,000 -7,181,000 1,825,000 -18,650,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-09 2022-08-11 2022-11-07 2023-03-06
Comprehensive Income/Loss -8,470,000 -10,168,000 118,000 -24,458,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -8,503,000 -10,170,000 118,000 -24,458,000
Other Comprehensive Income/Loss 0 0 118,000 29,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-09 2022-08-11 2022-11-07 2023-03-06
Basic Earnings Per Share 0 0 0 -1
Benefits Costs and Expenses 8,901,000 0 0 33,519,000
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 8,901,000 9,335,000 6,871,000 33,519,000
Diluted Earnings Per Share 0 0 0 -1
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -8,470,000 -10,168,000 83,000 -24,487,000
Income/Loss From Continuing Operations Before Tax -8,470,000 -10,168,000 8,319,000 -24,487,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating 1,082,000 1,066,000 81,000 2,172,000
Net Income/Loss -8,470,000 -10,168,000 83,000 -24,487,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -8,470,000 -10,168,000 83,000 -24,487,000
Net Income/Loss Available To Common Stockholders, Basic -8,470,000 -10,168,000 83,000 -24,487,000
Operating Expenses 7,841,000 9,335,000 6,871,000 30,328,000
Operating Income/Loss -7,410,000 -9,121,000 1,448,000 -21,296,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 431,000 214,000 8,319,000 9,032,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-07 2021-08-10 2021-11-12 2022-03-02
Assets 108,102,000 99,030,000 88,756,000 80,125,000
Current Assets 102,046,000 93,374,000 83,158,000 74,328,000
Current Liabilities 44,658,000 45,282,000 46,374,000 46,055,000
Equity 61,810,000 52,156,000 40,852,000 32,605,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 61,810,000 52,156,000 40,852,000 32,605,000
Liabilities 46,292,000 46,874,000 47,904,000 47,520,000
Liabilities And Equity 108,102,000 99,030,000 88,756,000 80,125,000
Noncurrent Assets 6,056,000 5,656,000 5,598,000 5,797,000
Noncurrent Liabilities 0 0 1,530,000 1,465,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-07 2021-08-10 2021-11-12 2022-03-02
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 33,415,000 -19,395,000 -4,264,000 5,066,000
Net Cash Flow, Continuing 33,415,000 -19,395,000 -4,264,000 5,066,000
Net Cash Flow From Financing Activities 33,365,000 241,000 43,000 33,646,000
Net Cash Flow From Financing Activities, Continuing 33,365,000 241,000 43,000 33,646,000
Net Cash Flow From Investing Activities 10,835,000 -22,135,000 6,291,000 -998,000
Net Cash Flow From Investing Activities, Continuing 10,835,000 -22,135,000 6,291,000 -998,000
Net Cash Flow From Operating Activities -10,785,000 2,499,000 -10,598,000 -27,582,000
Net Cash Flow From Operating Activities, Continuing -10,785,000 2,499,000 -10,598,000 -27,582,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-07 2021-08-10 2021-11-12 2022-03-02
Comprehensive Income/Loss -936,000 -11,775,000 -12,830,000 -35,110,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -934,000 -11,779,000 -12,830,000 -35,110,000
Other Comprehensive Income/Loss 0 0 -12,830,000 -30,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-07 2021-08-10 2021-11-12 2022-03-02
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses 12,936,000 11,775,000 12,829,000 0
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses 12,936,000 11,775,000 12,829,000 42,908,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -936,000 -11,775,000 -12,829,000 -35,080,000
Income/Loss From Continuing Operations Before Tax -936,000 -11,775,000 -12,829,000 12,000,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB -2,400,000
Interest Expense, Operating 1,028,000 1,077,000 1,092,000 4,295,000
Net Income/Loss -936,000 -11,775,000 -12,829,000 -35,080,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -936,000 -11,775,000 -12,829,000 -35,080,000
Net Income/Loss Available To Common Stockholders, Basic -936,000 -11,775,000 -12,829,000 -35,080,000
Operating Expenses 11,940,000 10,731,000 11,768,000 42,908,000
Operating Income/Loss 60,000 -10,731,000 -11,768,000 -30,908,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 12,000,000 0 0 12,000,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-07 2020-08-05 2020-11-09 2021-03-17
Assets 94,442,000 87,236,000 79,936,000 74,154,000
Current Assets 90,647,000 83,338,000 73,974,000 67,650,000
Current Liabilities 3,302,000 38,698,000 39,003,000 39,475,000
Equity 56,608,000 48,463,000 39,182,000 32,986,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 56,608,000 48,463,000 39,182,000 32,986,000
Liabilities 37,834,000 38,773,000 40,754,000 41,168,000
Liabilities And Equity 94,442,000 87,236,000 79,936,000 74,154,000
Noncurrent Assets 3,795,000 3,898,000 5,962,000 6,504,000
Noncurrent Liabilities 0 0 1,751,000 1,693,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-07 2020-08-05 2020-11-09 2021-03-17
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 45,245,000 -5,554,000 -31,734,000 1,445,000
Net Cash Flow, Continuing 45,245,000 -5,554,000 -31,734,000 1,445,000
Net Cash Flow From Financing Activities 34,877,000 -90,000 0 35,232,000
Net Cash Flow From Financing Activities, Continuing 34,877,000 -90,000 0 35,232,000
Net Cash Flow From Investing Activities 18,274,000 3,130,000 -24,126,000 -3,580,000
Net Cash Flow From Investing Activities, Continuing 18,274,000 3,130,000 -24,126,000 -3,580,000
Net Cash Flow From Operating Activities -7,906,000 -8,594,000 -7,608,000 -30,207,000
Net Cash Flow From Operating Activities, Continuing -7,906,000 -8,594,000 -7,608,000 -30,207,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-07 2020-08-05 2020-11-09 2021-03-17
Comprehensive Income/Loss -9,822,000 -9,409,000 -10,512,000 -42,713,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -9,822,000 -9,397,000 -10,512,000 -42,713,000
Other Comprehensive Income/Loss 0 0 -10,512,000 -19,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2020-05-07 2020-08-05 2020-11-09 2021-03-17
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -9,822,000 -9,409,000 -10,486,000 -42,694,000
Income/Loss From Continuing Operations Before Tax -9,822,000 -9,409,000 -10,486,000 -45,094,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB -2,400,000
Interest Expense, Operating 220,000 904,000 918,000 3,033,000
Net Income/Loss -9,822,000 -9,409,000 -10,486,000 -42,694,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -9,822,000 -9,409,000 -10,486,000 -42,694,000
Net Income/Loss Available To Common Stockholders, Basic -9,822,000 -9,409,000 -10,486,000 -42,694,000
Operating Expenses 9,880,000 8,631,000 9,637,000 40,181,000
Operating Income/Loss -9,880,000 -8,631,000 -9,637,000 -40,181,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-07 2019-08-07 2019-11-06 2020-03-13
Assets 85,979,000 81,250,000 76,074,000 68,424,000
Current Assets 84,677,000 79,739,000 74,040,000 64,983,000
Current Liabilities 3,062,000 4,281,000 4,330,000 3,351,000
Equity 82,761,000 76,845,000 71,653,000 65,015,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 82,761,000 76,845,000 71,653,000 65,015,000
Liabilities 3,218,000 4,405,000 4,421,000 3,409,000
Liabilities And Equity 85,979,000 81,250,000 76,074,000 68,424,000
Noncurrent Assets 1,302,000 1,511,000 2,034,000 3,441,000
Noncurrent Liabilities 0 0 91,000 58,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-07 2019-08-07 2019-11-06 2020-03-13
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 14,156,000 -4,575,000 -9,252,000 -1,030,000
Net Cash Flow, Continuing 14,156,000 -4,575,000 -9,252,000 -1,030,000
Net Cash Flow From Financing Activities 3,000 212,000 4,000 423,000
Net Cash Flow From Financing Activities, Continuing 3,000 212,000 4,000 423,000
Net Cash Flow From Investing Activities 21,070,000 263,000 -2,028,000 25,955,000
Net Cash Flow From Investing Activities, Continuing 21,070,000 263,000 -2,028,000 25,955,000
Net Cash Flow From Operating Activities -6,917,000 -5,050,000 -7,228,000 -27,408,000
Net Cash Flow From Operating Activities, Continuing -6,917,000 -5,050,000 -7,228,000 -27,408,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-07 2019-08-07 2019-11-06 2020-03-13
Comprehensive Income/Loss -7,479,000 -7,001,000 -6,090,000 -28,170,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -7,451,000 -6,974,000 -6,101,000 -28,170,000
Other Comprehensive Income/Loss 0 0 0 37,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2019-05-07 2019-08-07 2019-11-06 2020-03-13
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -7,479,000 -7,001,000 -6,090,000 -28,207,000
Income/Loss From Continuing Operations Before Tax -7,479,000 -7,001,000 -6,090,000 -28,207,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -7,479,000 -7,001,000 -6,090,000 -28,207,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -7,479,000 -7,001,000 -6,090,000 -28,207,000
Net Income/Loss Available To Common Stockholders, Basic -7,479,000 -7,001,000 -6,090,000 -28,207,000
Operating Expenses 8,026,000 7,521,000 6,543,000 30,080,000
Operating Income/Loss -8,026,000 -7,521,000 -6,543,000 -30,080,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2018-08-07 2018-11-07 2019-03-07
Assets UNPUB 104,716,000 98,805,000 91,906,000
Current Assets UNPUB 104,590,000 98,677,000 91,152,000
Current Liabilities UNPUB 3,125,000 2,451,000 2,477,000
Equity UNPUB 101,591,000 96,354,000 89,429,000
Equity Attributable To Noncontrolling Interest UNPUB 0 0 0
Equity Attributable To Parent UNPUB 101,591,000 96,354,000 89,429,000
Liabilities UNPUB 3,125,000 2,451,000 2,477,000
Liabilities And Equity UNPUB 104,716,000 98,805,000 91,906,000
Noncurrent Assets UNPUB 126,000 128,000 754,000
Noncurrent Liabilities UNPUB 0 0 0
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2018-08-07 2018-11-07 2019-03-07
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow UNPUB UNPUB -64,838,000 1,608,000
Net Cash Flow, Continuing UNPUB UNPUB -64,838,000 1,608,000
Net Cash Flow From Financing Activities UNPUB UNPUB -1,064,000 99,376,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB -1,064,000 99,376,000
Net Cash Flow From Investing Activities UNPUB UNPUB -58,637,000 -79,894,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB -58,637,000 -79,894,000
Net Cash Flow From Operating Activities UNPUB UNPUB -5,137,000 -17,874,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB -5,137,000 -17,874,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2018-08-07 2018-11-07 2019-03-07
Comprehensive Income/Loss UNPUB -5,317,000 -5,906,000 -20,665,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB -5,317,000 -6,746,000 -20,665,000
Other Comprehensive Income/Loss UNPUB 0 0 -20,665,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB 2018-08-07 2018-11-07 2019-03-07
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB -5,317,000 -5,906,000 -20,648,000
Income/Loss From Continuing Operations Before Tax UNPUB -5,317,000 -5,906,000 -20,648,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss UNPUB -5,317,000 -5,906,000 -20,648,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB 0 0 0
Net Income/Loss Attributable To Parent UNPUB -5,317,000 -5,906,000 -20,648,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB -5,317,000 -5,906,000 -20,648,000
Operating Expenses UNPUB 5,470,000 6,332,000 21,878,000
Operating Income/Loss UNPUB -5,470,000 -6,332,000 -21,878,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB 0 0 0
Preferred Stock Dividends And Other Adjustments UNPUB 0 0 0
Revenues UNPUB 0 0 0
Calendar
20 May 2024 (Time UTC) Actual Previous Consensus
★
11:30
United States
5.165
★
11:30
United States
5.250
★
11:30
United States
★
11:30
United States
★
10:30
United States
★★
09:00
United States
★★
09:00
United States
★★
08:45
United States
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-5400.000
-17800.000
★
15:30
United States
-66000.000
-60000.000
★
15:30
United States
59500.000
53700.000
★
15:30
United States
-116600.000
-135800.000
★★
15:30
United States
3200.000
4400.000
★
15:30
United States
203000.000
215400.000
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:VRCA240517P00007500 OPASPS Put American 100 7.5 BATO 2024-05-17
O:VRCA240517P00005000 OPASPS Put American 100 5 BATO 2024-05-17
O:VRCA240517P00002500 OPASPS Put American 100 2.5 BATO 2024-05-17
O:VRCA240517C00007500 OCASPS Call American 100 7.5 BATO 2024-05-17
O:VRCA240517C00005000 OCASPS Call American 100 5 BATO 2024-05-17
O:VRCA240517C00002500 OCASPS Call American 100 2.5 BATO 2024-05-17
O:VRCA240517P00012500 OPASPS Put American 100 12.5 BATO 2024-05-17
O:VRCA240517P00010000 OPASPS Put American 100 10 BATO 2024-05-17
O:VRCA240517C00012500 OCASPS Call American 100 12.5 BATO 2024-05-17
O:VRCA240517C00010000 OCASPS Call American 100 10 BATO 2024-05-17
O:VRCA240419P00010000 OPASPS Put American 100 10 BATO 2024-04-19
O:VRCA240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:VRCA240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:VRCA240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:VRCA240419C00010000 OCASPS Call American 100 10 BATO 2024-04-19
O:VRCA240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:VRCA240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:VRCA240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:VRCA240315P00010000 OPASPS Put American 100 10 BATO 2024-03-15
O:VRCA240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:VRCA240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:VRCA240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:VRCA240315C00010000 OCASPS Call American 100 10 BATO 2024-03-15
O:VRCA240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:VRCA240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:VRCA240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:VRCA240216P00012500 OPASPS Put American 100 12.5 BATO 2024-02-16
O:VRCA240216P00010000 OPASPS Put American 100 10 BATO 2024-02-16
O:VRCA240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:VRCA240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:VRCA240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:VRCA240216C00012500 OCASPS Call American 100 12.5 BATO 2024-02-16
O:VRCA240216C00010000 OCASPS Call American 100 10 BATO 2024-02-16
O:VRCA240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:VRCA240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:VRCA240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:VRCA240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:VRCA240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:VRCA240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:VRCA240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:VRCA240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:VRCA240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:VRCA231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:VRCA231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:VRCA231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:VRCA231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:VRCA231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:VRCA231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:VRCA231117P00012500 OPASPS Put American 100 12.5 BATO 2023-11-17
O:VRCA231117P00010000 OPASPS Put American 100 10 BATO 2023-11-17
O:VRCA231117P00007500 OPASPS Put American 100 7.5 BATO 2023-11-17
O:VRCA231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:VRCA231117P00002500 OPASPS Put American 100 2.5 BATO 2023-11-17
O:VRCA231117C00012500 OCASPS Call American 100 12.5 BATO 2023-11-17
O:VRCA231117C00010000 OCASPS Call American 100 10 BATO 2023-11-17
O:VRCA231117C00007500 OCASPS Call American 100 7.5 BATO 2023-11-17
O:VRCA231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:VRCA231117C00002500 OCASPS Call American 100 2.5 BATO 2023-11-17
O:VRCA231020C00005000 OCASPS Call American 100 5 BATO 2023-10-20
O:VRCA231020C00002500 OCASPS Call American 100 2.5 BATO 2023-10-20
O:VRCA231020P00010000 OPASPS Put American 100 10 BATO 2023-10-20
O:VRCA231020P00007500 OPASPS Put American 100 7.5 BATO 2023-10-20
O:VRCA231020P00005000 OPASPS Put American 100 5 BATO 2023-10-20
O:VRCA231020P00002500 OPASPS Put American 100 2.5 BATO 2023-10-20
O:VRCA231020C00010000 OCASPS Call American 100 10 BATO 2023-10-20
O:VRCA231020C00007500 OCASPS Call American 100 7.5 BATO 2023-10-20
O:VRCA230915P00012500 OPASPS Put American 100 12.5 BATO 2023-09-15
O:VRCA230915P00010000 OPASPS Put American 100 10 BATO 2023-09-15
O:VRCA230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:VRCA230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:VRCA230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:VRCA230915C00012500 OCASPS Call American 100 12.5 BATO 2023-09-15
O:VRCA230915C00010000 OCASPS Call American 100 10 BATO 2023-09-15
O:VRCA230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:VRCA230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:VRCA230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:VRCA230818P00015000 OPASPS Put American 100 15 BATO 2023-08-18
O:VRCA230818P00012500 OPASPS Put American 100 12.5 BATO 2023-08-18
O:VRCA230818P00010000 OPASPS Put American 100 10 BATO 2023-08-18
O:VRCA230818P00007500 OPASPS Put American 100 7.5 BATO 2023-08-18
O:VRCA230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:VRCA230818P00002500 OPASPS Put American 100 2.5 BATO 2023-08-18
O:VRCA230818C00015000 OCASPS Call American 100 15 BATO 2023-08-18
O:VRCA230818C00012500 OCASPS Call American 100 12.5 BATO 2023-08-18
O:VRCA230818C00010000 OCASPS Call American 100 10 BATO 2023-08-18
O:VRCA230818C00007500 OCASPS Call American 100 7.5 BATO 2023-08-18
O:VRCA230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:VRCA230818C00002500 OCASPS Call American 100 2.5 BATO 2023-08-18
News Stream
Health Health
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1st half of 2025
GlobeNewswire Inc. • 5d ago
Stocks Earnings Releases and Operating Results
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
– Reports YCANTH® revenue of $3.2M for first quarter of 2024 –
GlobeNewswire Inc. • 1w ago
Calendar Calendar of Events
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
WEST CHESTER, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica Pharmaceuticals’ President and Chief Executive Officer, will present at the following investor conferences:
GlobeNewswire Inc. • 1w ago
Calendar Calendar of Events
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
WEST CHESTER, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 13, 2024 to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024.
GlobeNewswire Inc. • 1w ago
Calendar Calendar of Events
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
WEST CHESTER, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica’s President & Chief Executive Officer, will present at the upcoming 23rd Annual Needham Virtual Healthcare Conference, which is being held virtually from April 8-11, 2024.
GlobeNewswire Inc. • 1mo ago
stocks Licensing Agreements
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
NCE status provides a minimum of five years of regulatory exclusivity
GlobeNewswire Inc. • 1mo ago
Stocks Licensing Agreements
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
NCE status provides a minimum of five years of regulatory exclusivity
GlobeNewswire Inc. • 1mo ago
Stocks Earnings Releases and Operating Results
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
– Reports YCANTH™ revenue of $1.9M for fourth quarter and $4.7M for full year 2023 –
GlobeNewswire Inc. • 2mo ago
Calendar Calendar of Events
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
WEST CHESTER, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that they will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference, which will be held in Boston, Massachusetts.
GlobeNewswire Inc. • 2mo ago
News Law & Legal Issues
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
Lawsuit alleges false and misleading advertising and promotion of unapproved cantharidin-containing drugs by Dormer Laboratories in violation of federal and state law
GlobeNewswire Inc. • 3mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT